Michael S. Turner Sells 9,672 Shares of 908 Devices Inc. (NASDAQ:MASS) Stock

908 Devices Inc. (NASDAQ:MASS) insider Michael S. Turner sold 9,672 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $2.33, for a total value of $22,535.76. Following the transaction, the insider now owns 24,603 shares of the company’s stock, valued at approximately $57,324.99. This trade represents a 28.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

908 Devices Stock Up 11.8 %

MASS opened at $2.65 on Thursday. The company’s 50-day moving average price is $2.35 and its 200 day moving average price is $3.26. 908 Devices Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $7.91. The firm has a market cap of $92.27 million, a price-to-earnings ratio of -1.50 and a beta of 0.98.

Institutional Trading of 908 Devices

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its holdings in shares of 908 Devices by 88.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 245,176 shares of the company’s stock worth $1,263,000 after purchasing an additional 114,987 shares during the last quarter. Renaissance Technologies LLC lifted its stake in 908 Devices by 79.4% in the second quarter. Renaissance Technologies LLC now owns 195,500 shares of the company’s stock valued at $1,007,000 after buying an additional 86,500 shares during the last quarter. Marshall Wace LLP bought a new stake in 908 Devices in the second quarter valued at $229,000. Squarepoint Ops LLC acquired a new position in shares of 908 Devices during the second quarter valued at $250,000. Finally, AQR Capital Management LLC bought a new position in shares of 908 Devices during the second quarter worth about $585,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Leerink Partners reiterated a “market perform” rating and set a $4.00 price objective (down from $12.00) on shares of 908 Devices in a research note on Wednesday, November 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 908 Devices in a research report on Saturday, February 1st. Leerink Partnrs lowered 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Stifel Nicolaus lowered their price target on 908 Devices from $17.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Finally, Stephens reissued an “overweight” rating and set a $6.00 price target on shares of 908 Devices in a research report on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.33.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.